Tag Archives: product

Apple is facing increasing lawsuits over casino-style gaming | Instant News


Apple Inc on Tuesday was hit by a new class action lawsuit on Tuesday accusing it of profiting from illegal gambling by offering casino-style games made by South Korea-based DoubleU Games Co Ltd through its popular app store.

“Apple permits and facilitates illegal gambling by operating as a casino without a license,” said the plaintiffs, Oregon resident Joshua McDonald and Alabama resident Michael Helsel, in complaints filed in federal court in San Jose, California.

To read the full story on Westlaw Today, click here: bit.ly/31VIXWk

.



image source

Apple invests $50 million in music distributors to support independent singers | Instant News


Apple.
AAPL,
+ 2.85%

Is investing in independent music artists.

The technology giant has raised US$50 million in financing for UnitedMasters, a three-year-old artist service company dedicated to helping musicians distribute and sell their music while allowing them to retain their copyrights.

UnitedMasters received $70 million in support in Silicon Valley in 2017. It is an alternative to the traditional major record company system, which usually requires artists to give up their music rights in exchange for pre-emption rights, distribution rights, marketing rights and promotion rights. Artists choose to pay a monthly subscription fee of $5, or pay a 10% fee to UnitedMasters and retain ownership of their music. The company has released music by more than 1 million artists, including NLE Choppa, Lil Tecca, Lil XXEL, and the recent breakthrough films Tobe Nwigwe and Curtis Roach. Their “House of Boredom” was on TikTok during the pandemic blockade. All the rage.

This investment is related to how Apple operates the world’s second largest streaming media service through subscription, positioning Apple itself as creator-friendly. This investment also shows that new deals by independent artists to bring music to the world are multiplying and dominating the industry.

An expanded version of this article will be displayed on WSJ.com.

Top stories from WSJ.com:

.



image source

Epredia And Paige Announce Global Commercial Distribution Agreement For Digital Pathology Software | Country | Instant News


PORTSMOUTH, NH, 17 March 2021 / PRNewswire / – Epredia, a global leader in precision cancer diagnosis, and Paige, a global leader in AI-based diagnostic software in pathology, today announced that they have signed a commercial distribution agreement for a comprehensive portfolio of Paige diagnostic software solutions.

Under the terms of this agreement, Epredia has been appointed as the global distribution partner of Paige’s entire portfolio of imaging diagnostic solutions. In addition, Epredia will have exclusive distribution rights on Japan. In the second quarter of 2021, Epredia will start commercializing the Paige solution together with Epredia’s existing products. United States of America and the major European powers, further strengthening its comprehensive digital pathology portfolio which includes the best-in-class CE-marked 3DHistech P1000 scanner *.

The Paige portfolio includes the Paige Platform, a comprehensive imaging solution consisting of a fast trackless footprint viewer, storage capabilities and AI-based diagnostic software to help pathologists review cases and support their overall workflow.

The FDA approved and CE marked Paige platform features FullFocus ™, an intuitive and responsive viewer for pathology scanning that supports primary diagnosis and its Data Management solution for pathology scan storage. The Paige platform is designed to be compatible with existing pathology solutions, including most laboratory scanners, monitors and information systems.

Paige’s AI-based diagnostic software solution is designed to increase the number of cases that can be reviewed and with greater confidence and accuracy. Currently Paige Prostate and Paige Breast are CE marked and available for outside clinical use United States of America. Paige Prostate RUO and Paige Breast RUO are research use-only solutions available at United States of America.

“We are very excited to enter into this partnership with Paige to commercialize its highly innovative portfolio of AI-based digital pathology solutions,” he explained. John Marotta, President, Epredia and Chief Executive Officer, PHC Holdings Corporation. “We believe that digital pathology is an important part of future cancer diagnosis that can greatly improve patient care. We see enormous potential in Paige’s portfolio and believe that it complements our portfolio perfectly. This deal provides us with access to a portfolio that is diverse. highly innovative products that enable us to realize our mission to improve lives by improving cancer diagnostics for patients. “

“This commercial partnership with Epredia is an exciting step for Paige and we are delighted to be working with one of the leading companies in the field of anatomical pathology. Epredia’s extensive global commercial reach will support our efforts to expand our geographic footprint,” said Epredia. Leo Grady, Ph.D., Executive Director of Paige. “Our goal is to transform the diagnostic space by offering a portfolio of software applications that help optimize patient outcomes by enabling pathologists to unlock insights from each sample and return results to doctors and patients more quickly. This commercial agreement will help put our solutions into more hands. pathologists around the world to help patients get the most timely and effective treatment. “

* Regulatory requirements for the 3DHistech P1000 scanner vary by country, please contact your commercial partner to confirm use of an approved scanner in your country.

Epredia is a global leader in the field of anatomical pathology, providing comprehensive solutions for precision cancer diagnosis and tissue diagnostics. Supported by major brands, including Erie Scientific, Menzel-Gläser, Microm, Shandon, and Richard-Allan Scientific, the Epredia portfolio includes microscope slides, instruments and consumables. Epredia was founded following the acquisition of the Pathology Anatomical Pathology business by PHC Holdings by PHC Holdings in 2019. Epredia has its main site at United States of America, that great Britain, German, Switzerland and China with a total of about 1,200 employees. Epredia is committed to achieving its mission of improving lives by improving cancer diagnostics for patients worldwide. For more information about Epredia and its products, please visit www.epredia.com.

Paige was founded in 2017 by Thomas Fuchs, Dr.Sc. and colleagues from the Memorial Sloan Kettering Cancer Center (MSK). The company makes computational pathology products designed so that patients and their care teams can make effective and more informed treatment decisions. With a new class of AI-based technology positioned to drive the future of diagnostics, Paige created a platform to bring this new technology to pathologists to transform their workflows and increase diagnostic confidence and productivity. Paige’s products provide pathologists and oncologists with insights so that they can arrive efficiently at a more precise diagnosis for a patient. Paige is the first company to receive an FDA breakthrough designation for a computational pathology product.

.



image source

Catalents to Expand Production of the J&J Covid-19 Vaccine in Italy | Instant News


Contract drug manufacturers

Catalens Inc.

CTLT -2.95%

is planning a massive expansion of production of the Covid-19 vaccine in Europe, allowing it to make more doses

Johnson & Johnson‘s

JNJ 0.59%

shot, said people familiar with the matter.

Catalent will present a second J&J vaccine production line at its plant in Anagni, Italy, during the fourth quarter, the sources said. The expansion has the potential to double the production of the Covid-19 vaccine factory, said one source.

This increase will help increase the supply of the Covid-19 vaccine in European Union, which is stuck with late signing of contracts, delivery problems and difficulty distributing shots in some member states.

European regulators recently phased out the J&J vaccine, although distribution is not expected to start until next month.

J&J has agreed to give the EU 200 million doses this year, and the EU has the option to buy another 200 million. The company said it was confident it would meet its full year target.

NIAID director Anthony Fauci said it was risky to pull back on public health measures, as cases can peak and then recover, as has happened in Europe.

Johnson & Johnson declined to comment. The company has registered nearly a dozen companies to helped produce Covid-19 shots, including

Merck

& Co. and

Sanofi TO

.

Catalent, from Somerset, NJ, is one of the world’s largest contract drug makers.

The company agreed to buy a 300,000 square foot facility in Italy in 2019 and take over ownership in January 2020. The company adapted it over the past year to help make a Covid-19 vaccine.

Catalent is currently helping to manufacture the vaccine developed by

AstraZeneca

PLC and the University of Oxford at the facility.

Initial production of the J&J vaccine at the facility is scheduled to begin in the second quarter, according to people with knowledge of the matter. Catalent hopes to eventually produce hundreds of millions of doses.

The expansion will increase the plant’s ability to take key steps in vaccine production. The step, known as a fill-finish, involves filling the vial with the vaccine, closing the vial, and preparing the product for shipment.

Health authorities around the world are looking forward to it J&J shot, in part because it can be stored in a refrigerator instead of a freezer, making shipping and handling easier than other Covid-19 shoots.

J & J is also only one injection, unlike the vaccine from

Modern Inc.,

Pfizer Inc.

and partners

BioNTech SE

which requires two doses weeks apart.

Catalent is also completing refills for the J&J vaccine at its Bloomington, Ind., Plant. The Italian line will work at the same speed as Indiana, filling 400 bottles per minute, the people said. Each bottle contains 5 doses.

STAY INFORMATION

Get coronavirus briefings six days a week, and a weekly Health bulletin after the crisis has died down: Register here.

Write to Jared S. Hopkins at [email protected]

Copyright © 2020 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Appears in the print issue of March 17, 2021 as ‘A Catalent for Expanding J&J Dose Production.’

.



image source

Tesla faces a race with Volkswagen as the German auto giant targets the cost of batteries and new gigafactories | Instant News


The race to dominate the electric vehicle industry may be tighter as Volkswagen, Germany’s auto giant and looming rival Tesla, revealed plans on Monday to reduce battery costs and operate an extensive charging network.

The first-ever “Power Day” reminds us of electric car maker Tesla
TSLA,
+ 2.05%

Much-loved “Battery Day”, the German group which owns the Volkswagen, Audi and Porsche brands said it will rely on six gigafactories in Europe to secure supplies as the industry faces looming shortages.

Shares in the Volkswagen Group
SWEAR,
+ 3.55%

VWAGY,
+ 7.17%

VWAPY,
+ 2.93%

surged about 3% on Monday as the company’s top executives outlined a road map for technology expansion.

Electric vehicles have become the company’s “core business” in Wolfsburg, Germany, said Herbert Diess, chairman of the group’s management board, and his new plans come as the battle for domination of the fast-growing electric vehicle space heats up.

Also read: Forget about Nio and XPeng. This company and Tesla will be the top two electric vehicle games by 2025, said UBS.

According to analysts at UBS, EVs could achieve 100% penetration of the auto market by 2040. Over the next few years, Swiss banks project that Volkswagen and Tesla will emerge as market leaders, with German companies expected to catch up with Tesla. in terms of the total volume of electric vehicles sold next year.

Volkswagen eliminated Tesla from its top ranking in the European EV market in 2020 and now has a 20% to 25% market share in this key region. Europe is the second largest electric vehicle market in the world after China, which is home to domestic EV manufacturers including Nio
NIO,
-1.25%
,
XPeng
XPEV,
+ 0.63%

and WORLD
1211,
-2.88%
.

As auto companies scramble to pivot across sectors for electric mobility, UBS said it expects that the supply of battery cells needed to meet demand will face “regional tightness this year and global shortages by 2025.”

To secure the batteries needed for expansion, Volkswagen said it would rely on six gigafactors by 2030. The first plants will be in the Swedish cities of Salzgitter and Skellefteå, where Volkswagen is building a plant with partner Northvolt.

Read more: Volkswagen and Goldman Sachs-backed Northvolt takes over Cuberg Silicon Valley as the electric vehicle battery race heats up

Northvolt said on Monday that it had received a $ 14 billion order from Volkswagen for premium battery cells. The German group also increased its stake in the Swedish company, which was founded by former Tesla employees with supporters including Goldman Sachs.
GS,
-0.79%

and Spotify
POINT,
+ 1.99%

Chief Executive Daniel Ek.

In addition, Volkswagen said it would seek to lower its battery costs – a key factor in lowering total vehicle costs – by up to 50% over the next decade.

Cost savings of some form will be seen from 2023 onwards, Volkswagen said, as the group plans to launch a new integrated battery cell that will be installed in 80% of its electric vehicles by 2030.

“We aim to reduce the cost and complexity of a battery and at the same time increase its range and performance,” said Thomas Schmall, Volkswagen technology board member and head of its technology roadmap. “This will ultimately make e-mobility affordable and become the dominant driving technology.”

Plus: Buy these 3 stock batteries to play at the electric vehicle party, but stay away from these companies, says UBS

To support broad consumer adoption of electric vehicles, Volkswagen plans to increase its European vehicle charging network fivefold by 2025. In the next few years, the company aims to operate 18,000 public fast charging points, including 8,000 in partnership with major oil company BP.
BP,
-2.26%
.

Volkswagen will build 3,500 more charging points in North America by the end of 2021 through its US subsidiary Electrify America, as well as 17,000 charging points in China by 2025 through a joint venture.

Automotive analyst Matthias Schmidt told MarketWatch that “giants” like Volkswagen “are slowly getting up and starting to show that size matters in terms of the future of electricity [that] the rules forced their entry. ”

More: Tesla is on the decline, SUVs are king, and there is more insight from this premier electric vehicle market

European carmakers are being pushed to produce more electric vehicles under threat of hundreds of millions of euros in fines from the European Union over binding fleet emissions targets.

The race towards electric mobility is also supported on the demand side, with many European governments offering thousands of dollars in tax breaks and subsidies for consumers to choose electric vehicles.

“VW announced a large cost advantage from increased production, deciding to integrate vertically in helping to cut BEV costs towards a price balance, which is critical after subsidy scaffolding is slowly being removed,” said Schmidt, who is also the publisher. European Electric Car Report.

.



image source